UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG, with a price target of CHF116.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and Novartis AG. According to TipRanks, Weston has an average return of 11.6% and an 81.05% success rate on recommended stocks.
In addition to UBS, Novartis AG also received a Hold from Jefferies’s Benjamin Jackson CFA in a report issued today. However, on the same day, Goldman Sachs maintained a Sell rating on Novartis AG (Six Swiss: NOVN).
Based on Novartis AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion. In comparison, last year the company earned a revenue of CHF13.17 billion and had a net profit of CHF3.19 billion
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
- Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
- Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
- Novartis reports Q4 core EPS $2.03 vs. $1.98 last year
- Novartis sees FY26 net sales up low single digits vs. last year
